Abstract 342P
Background
This study aimed to assess breast cancer (BC) patients' knowledge and perception of fertility risks and preservation, and to determine factors that impact fertility preservation(FP) patient decision making.
Methods
We performed a cross-sectional study including 70 BC patients ≤ 45 year-old. Patients were surveyed using a 29 item questionnaire assessing their personal experience and knowledge about fertility risks and FP treatments. A knowledge score (0-12) was calculated with 1 point awarded for each correct answer. Statistical associations between socio-demographic characteristics, personal experience and knowledge score were analyzed.
Results
Mean age was 34 year-old. Thirty-seven patients had a college degree and 80% were married. Previous pregnancy/live birth were reported in 77%/72% of patients. Twenty-seven percent of patients had prior contact with infertility. Fifty-five patients were informed about infertility risks related to BC treatment. Only 62.8% of patients received information about FP treatments. Thirty-five patients were referred to FP consultation of whom 12 patients received FP treatments. Embryos/oocytes freezing were the main used options. The main reasons for skipping FP treatments were lack of pregnancy desire (38.6%) and insufficient provided information (30%). “Complexity of FP procedure” and “fear of delaying cancer treatment” were reported in 8.6% and 4.3% of cases respectively. Mean knowledge score was 6(3 -11). Forty-six percent of patients believed that “FP treatment is related to an increased risk of cancer recurrence”. Only 61.4% of patients were aware that “freezed eggs remain available in the future whenever the patient is ready to use them”. Most of the patients (81.4%) were aware that having a spouse was not a prerequisite for FP treatment. Knowledge about FP treatments availability and costs was poor with more than half of patients overestimating costs and assuming the lack of FP treatment options. Only 60% of patients were aware of an operational legal framework for FP in Tunisia.
Conclusions
This study showed that FP baseline knowledge in BC patients is generally poor. Patient's access to clear and concise fertility information is the key for effective interventions for fertility preservation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
360P - Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study
Presenter: Yue Chai
Session: Poster session 03
361P - A phase II study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2- locally advanced breast cancer
Presenter: Jing Wu
Session: Poster session 03
362P - CYBERNEO trial: Update of results at 14 years of follow-up
Presenter: Syrine Ben Dhia
Session: Poster session 03
363P - High adipocytokines and IL-18bp serum levels are associated with lower objective response rate after neoadjuvant treatment in breast cancer patients with metabolic syndrome
Presenter: Larissa Mont'Alverne Arruda
Session: Poster session 03
365P - Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real-world study
Presenter: Baocheng Wang
Session: Poster session 03
366P - Artificial intelligence (AI)-powered assessment of complete and intense human epidermal growth factor receptor 2 (HER2)-positive tumor cell proportion in breast cancer: Predicting fluorescence in situ hybridization (FISH) positivity and response to HER2-targeted therapy
Presenter: Minsun Jung
Session: Poster session 03
367P - Sentinel lymph node biopsy (SLNB) in patients with locally advanced breast cancer (LABC): Descriptive, inferential and survival analysis
Presenter: Johanna Espejo Niño
Session: Poster session 03
368P - Impact of PET-CT-determined sarcopenia on survival and pathological complete response in breast cancer patients with neoadjuvant chemotherapy
Presenter: Gözde Tahtaci
Session: Poster session 03
369P - The impact of germline BRCA mutations in locally advanced, triple-negative breast cancer (TNBC) treated with platinum- based neoadjuvant chemotherapy
Presenter: Hadar Goldvaser
Session: Poster session 03
370P - LYMPHA surgery to reduce lymphedema following axillary node clearance: A new study at a London plastics centre
Presenter: Dorian Hobday
Session: Poster session 03